Structure-activity relationship of Kahalalide F synthetic analogues

Journal of Medicinal Chemistry

Volumn 51, Issue 16, 2008, Pages 4920-4931

  Jiménez, José C ^a,b   López Macià, Angel ^b,c   Gracia, Carol ^b   Varón, Sonia ^b,d   Carrascal, Marta ^b   Caba, Josep M ^a   Royo, Miriam ^b,d   Francesch, Andrés M ^c   Cuevas, Carmen ^c   Giralt, Ernest ^a,b   Albericio, Fernando ^a,b  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c PHARMAMAR S A   (Spain)

^d NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALIPHATIC CARBOXYLIC ACID; ANTINEOPLASTIC AGENT; KAHALALIDE F; PEPTIDE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CHEMICAL MODIFICATION; CYTOTOXICITY; DRUG STRUCTURE; HYDROPHOBICITY; IN VITRO STUDY; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY ANALYSIS; SOLID PHASE SYNTHESIS; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DEPSIPEPTIDES; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 50249173357     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8000828     Document Type: Article

References (25)

1. Hamann, M. T.; Scheuer, P. J. Kahalalide F: a bioactive depsipeptide from the sacoglossan mollusk Elysia rufescens and the green alga Bryopsis sp. J. Am. Chem. Soc. 1993, 115, 5825-5826.
2. Ashour, M.; Edrada, R.; Ebel, R.; Wray, V.; Waetjen, W.; Padmakumar, K.; Mueller, W. E. G.; Lin, W. H.; Proksch, P. Kahalalide derivatives from the Indian sacoglossan mollusk Elysia grandifolia. J. Nat. Prod. 2006, 69, 1547-1553.
3. Tilvi, S.; Naik, C. G. Tandem mass spectrometry of kahalalides: identification of two new cyclic depsipeptides, kahalalide R and S from Elysia grandifolia. J. Mass. Spectrom. 2007, 42, 70-80.
4. Hamann, M. T.; Otto, C. S.; Scheuer, P. J.; Dunbar, D. C. Kahalalides: bioactive peptides from a marine mollusk Elysia rufescens and its algal diet Bryopsis sp. J. Org. Chem. 1996, 61, 6594-6600.
5. Ciruelos, C.; Trigo, T.; Pardo, J.; Paz-Ares, L.; Estaun, N.; Cuadra, C.; Dominguez, M.; Marin, A.; Jimeno, J.; Izquierdo, M. A phase I clinical and pharmacokinetic (PK) study with kahalalide F (KF) in patients (pts) with advanced solid tumors (AST) with a continuous weekly (W) 1-h iv infusion schedule. Eur. J. Cancer 2002, 38 (Suppl. 7), S33.
6. Rademaker-Lakhai, J. M.; Horenblas, S.; Meinhardt, W.; Stokvis, E.; de Reijke, T. M.; Jimeno, J. M.; Lopez-Lazaro, L.; Lopez Martin, J. A.; Beijnen, J. H.; Schellens, J. H. M. Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer. Clin. Cancer Res. 2005, 11, 1854-1862.
7. Garcia-Rocha, M.; Bonay, P.; Avila, J. The antitumoral compound kahalalide F acts on cell lysosomes. Cancer Lett. 1996, 99, 43-50.
8. Janmaat, M. L.; Rodriguez, J. A.; Jimeno, J.; Kruyt, F. A. E.; Giaccone, G. Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. Mol. Pharmacol. 2005, 68, 502-510.
9. Suarez, Y.; Gonzalez, L.; Cuadrado, A.; Berciano, M.; Lafarga, M.; Munoz, A. Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells. Mol. Cancer Ther. 2003, 2, 863-872.
10. Finkel, E. Does cancer therapy trigger cell suicide? Science 1999, 286, 2256-2558.
11. Lopez-Macia, A.; Jimenez, J. C.; Royo, M.; Giralt, E.; Albericio, F. Synthesis and structure determination of kahalalide F. J. Am. Chem. Soc. 2001, 123, 11398-11401.
12. Jiménez, J. C.; Bayó, N.; Chavarria, B.; Lopez-Macia, A.; Royo, M.; Nicolas, E.; Giralt, E.; Albericio, F. Synthesis of peptides containing α,β-didehydroamino acids. Scope and limitations. Lett. Pept. Sci. 2002, 9, 135-141.
13. Höfle, G.; Steglich, W.; Vorbrueggen, H. New synthetic methods. 25. 4-Dialkylaminopyridines as aeylation catalysts. 4. Puridine syntheses. 1. 4-Dialkylaminopuridines as highly active aeylation catalysts. Angew. Chem., Int. Ed. Engl. 1978, 17, 569-583.
14. Monks, A.; Scudiero, D.; Scudiero, D; Skehan, P; Shoemaker, R; Pauli, K; Vistica, D; Hose, C; Langley, J; Cronise, P; Vaigro-Wolff, A. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 1991, 83, 757-766.
15. Joshi, R. M.; Chauan, V. S. Synthesis of Peptides Based on α,β-Didehydro-α-amino Acids. In Methods of Organic Chemistry, E22c; Goodman, M., Felix, A., Moroder, L, Toniolo, C., Eds.; Houben-Weyl: New York, 2003; Vol. 63, pp 6-662.
16. Goetz, G.; Yoshida, W. Y.; Scheuer, P. J. The absolute stereochemistry of kahalalide F. Tetrahedron 1999, 55, 7739-7746.
17. Bonnard, I.; Manzanares, I.; Rinehart, K. L. Stereochemistry of kahalalide F. J. Nat. Prod. 2003, 66, 1466-1470.
18. Shilabin, A. G.; Kasanah, N.; Wedge, D. E.; Hamann, M. T. Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies. J. Med. Chem. 2007, 50, 4340-4350.
19. Faircloth, G. T.; Elices, M.; Sasak, H.; Aviles, P. M.; Cuevas, C. Preparation of Kahalalide Antitumoral Compounds. PCT Int. Appl. WO 2004035613 A2 20040429, CAN 140:357671, 2004.
20. Dangles, O.; Guibe, F.; Balavoine, G.; Lavielle, S.; Marquet, A. Selective cleavage of the allyl and (allyloxy)carbonyl groups through palladium-catalyzed hydrostannolysis with tributyltin hydride. Application to the selective protection-deprotection of amino acid derivatives and in peptide synthesis. J. Org. Chem. 1987, 52, 4984-4993.
21. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82, 1107-1112.
22. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55-63.
23. Faircloth, G. T.; Stewart, D. A simple screening procedure for the quantitative measurement of cytotoxicity assay. J. Tissue Cult. Methods 1988, 11, 201-205.
24. Recently, a convergent methodology for the rapid synthesis of KF analogues has been developed in our group: Gracia, C.; Isidro-Llobet, A.; Cruz, L. J.; Acosta, G. A.; Alvarez, M.; Cuevas, C.; Giralt, E.; Albericio, F. Convergent approaches for the synthesis of the antitumoral peptide, kahalalide F. Study of orthogonal protecting groups. J. Org. Chem. 2006, 71, 7196-7204. However, it was not used for the generation of this set of compounds.
25. This compound was obtained as side product during cyclization with PyAOP/DIEA. See ref 11. This epimerization is totally avoided when DIPCDI/HOBt is used as cyclization method.